Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG (NOVN)

256
Delayed Quote. Delayed BATS EUROPE - 05/22 05:29:50 pm
98.3250 CHF   +0.28%
05/22 NOVARTIS : announces two positive US phase III programs in COPD for ..
05/21DJFor CVS, Big Bet On Pricey Medicines
05/21DJCVS to Buy Omnicare for $10.4 Billion
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Swiss Exchange
05/18/2015 05/19/2015 05/20/2015 05/21/2015 05/22/2015 Date
96.55(c) 97.55(c) 97.1(c) 98.05(c) 98.1(c) Last
4 302 586 3 442 794 3 691 430 4 119 135 3 212 313 Volume
+1.74% +1.04% -0.46% +0.98% +0.05% Change
More quotes
Financials ($)
Sales 2015 52 512 M
EBIT 2015 13 838 M
Net income 2015 12 707 M
Debt 2015 6 140 M
Yield 2015 2,70%
Sales 2016 53 722 M
EBIT 2016 14 498 M
Net income 2016 10 877 M
Debt 2016 4 575 M
Yield 2016 2,86%
PER 2015 17,42
PER 2016 23,59
EV / Sales 2015 5,46x
EV / Sales 2016 5,30x
Capitalization 280 360 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, Vaccines and Diagnostics, and Consumer Health.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers... 
Sector
Pharmaceuticals
Calendar
06/17 | 06:30pmShareholder meeting
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
05/22 NOVARTIS : announces two positive US phase III programs in COPD for QVA149 and N..
05/21DJFor CVS, Big Bet On Pricey Medicines
05/21DJCVS to Buy Omnicare for $10.4 Billion
05/21 NOVARTIS : drug Afinitor® extended progression-free survival in Phase III trial ..
05/21 NOVARTIS : drug Afinitor® extended progression-free survival in Phase III trial ..
05/20 NOVARTIS : Patent Issued for Substituted Indole Derivatives
05/20 InSite Vision Reports First Quarter 2015 Financial Results
05/20 NOVARTIS : announces two positive US phase III programs in COPD for QVA149 and N..
More news
Sector news : Pharmaceuticals - NEC
05/23 GERMANY'S MERCK EXPECTS DRUG DIVISIO : Euro am Sonntag
05/22DJAmgen Ends Psoriasis-Drug Partnership With AstraZeneca -- Update
05/22 AMGEN : ends work on experimental psoriasis drug
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/23 Tracking Tweedy Browne Portfolio - Q1 2015 Update
05/22 SEEKING ALPHA'S BIOTECH WEEKLY : J&J-Achillion Vs. Gilead, MannKind's Marketing,..
05/21 Novartis' Afinitor successful in Phase 3 study for expanded indication
05/21 ImmunoGen earns $5M milestone from Novartis
05/19 BIOSIMILARS VS GENERICS : History Does Not Repeat, It Rhymes


Comments 
Advertisement
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions